Contents

1 The Aqueous Interface of a Soluble Protein or the Birth of Epistructural Biology 1

1.1 The Aqueous Interface as Determined by the Structure of a Soluble Protein 2

1.2 Protein Dehydrons Generate Interfacial Tension: Breakdown of the Conventional Dielectric Theory at Nanoscales 6

1.3 The Aqueous Interface from a Structure-Centric Perspective: Many-Body Problem for the Drug Designer 10

1.4 Dehydrons Promote Protein Associations: A Structural Perspective. 13

1.5 Dehydron Stickiness: Epistructural View of Biomolecular Interfaces 16

1.6 Biomolecular Interfaces and Drug-Target Associations: A Glimpse at New Possibilities for Molecular Engineering 19

1.7 Biomolecular Interfaces Constrain the Architecture of Soluble Proteins 21

Problems. 30

References. 31

2 Electrostatic Exploration of Biomolecular Interfaces: The Chemical Function of Interfacial Water 35

2.1 Interfacial Tension and Non-Debye Polarization of Interfacial Water 35

2.2 Non-Debye Polarization of the Aqueous Interface of a Soluble Protein 39

2.3 Chemical Functionality of the Aqueous Interface: A Consequence of the Breakdown of Debye's Dielectric Picture 42

2.4 A New Twist on Enzyme Catalysis: Nanoscale Packing Defects as Catalytic Stimulators 48

Problems. 50

References. 51

3 Semiempirical Solution to the Protein Folding Problem Through a Combination of Structural and Epistructural Approaches 53
3.1 Structure-Centric Approach to Protein Folding: Cooperativity and Wrapping Delineate a Many-Body Problem 54
3.2 Hydrogen-Bond Wrapping Requires Cooperative Folding 56
3.3 Generating Cooperative Folding Trajectories 58
3.4 Wrapping Patterns Along Folding Pathways 62
3.5 Nanoscale Dielectric Theory of Folding Cooperativity: The Conventional "Effective Permittivity" Approach 67
3.6 The Dehydronic Field Commits the Chain to Fold 71
3.7 The Biomolecular Interface in Protein Folding: The Principle of Minimal Epistructural Distortion 72
3.8 What Did It Take to Solve the Protein Folding Problem? 78
Problems 79
References 81

4 Packing Defects and Protein Hydration: Dynamics of the Aqueous Interface 83
4.1 Dynamic Singularities of Biomolecular Interfaces 83
4.2 Impact of Protein Packing Defects on Interfacial Dynamics 84
4.3 Dehydrons Loosen up the Aqueous Interface 86
4.4 Displacing Loose Hydrating Molecules: A Blueprint for the Drug Designer 90
4.5 How Do Dehydrons Steer Interfacial Water? 92
Problems 93
References 95

5 Proteins in the Order–Disorder Twilight: Unstable Interfaces Promote Protein Aggregation 97
5.1 Dehydron Clusters and Disordered Regions 97
5.2 Semiclassical View of Discrete Dielectrics Around Dehydrons 99
5.3 Semiclassical Treatment of Dielectric Modulation of Interfacial Water Around Dehydrons 102
5.4 Dielectric Quenching in the p53 DNA-Binding Domain: A Study Case 106
5.5 Proteins with Dehydron Clusters: Structural View of the Order–Disorder Twilight 108

5.6 Inferring Dehydrons from Protein Sequence: Water-Exposed Backbone and Disorder Propensity 111
5.7 Misfolding and Aggregation: Massive Violation of Architectural Constraints for Protein Structure 115
Problems 120
References 124

6 Evolution of Protein Structure Degradation and Lessons for the Drug Designer 127
6.1 An Evolutionary Context for the Drug Designer 127
6.2 Comparing Protein Wrapping Across Species: Hallmarks of Nonadaptive Traits 129
6.3 Wrapping and Natural Selection 129
6.4 How Do Humans Cope with Inefficient Selection? 132
6.4.1 Regulatory Patterns Segregating Paralog Proteins 133
6.4.2 Wrapping Deficiency Causes Dosage Imbalance Causes Regulation Dissimilarity 136
6.5 Human Capacitance to Cope with Dosage Imbalances in Under-Wrapped Proteins 142
6.6 Fitness Catastrophes for the Human Species Arising from Nature's "Evolutionary Gambit" to Promote Interactome Complexity 143
6.7 Why Should the Drug Designer Be Mindful of Molecular Evolution? 145
6.8 Some Consequences for Evolutionary Technology 147
Problem 148
References 148

7 Chemical Functionality of the Aqueous Interface in Soluble Proteins 151
7.1 Dehydrons Induce Chemical Basicity in the Aqueous Interface 151
7.2 Exploring the Chemical Functionality of Dehydrons in Specific Proteins 156
7.3 The Dehydron as a Two-Step Catalytic Engine 161
7.4 Quantum Mechanical Exploration of Chemical Events Involving Dehydrons 161
7.5 Methodology for Quantum Mechanical Assessment of the Chemical Role of Dehydrons 163
7.6 Capturing Chemical Events Involving Dehydrons 165
Problem 172
References 172

8 The Biomolecular Interface as a Selectivity Filter for Drug-Based Targeted Therapy 175
8.1 The Control of Drug Specificity: An Imperative for Drug Design 176
8.2 Epistructural Drug Design: Ligands Wrap Protein Packing Defects upon Binding to the Target Protein 180
8.3 Poor Dehydron Wrappers Make Poor Drugs Even at High Affinity: The *Staurosporine* Lesson 182
8.4 The Biomolecular Interface as a Selectivity Filter 183
8.5 Epistructure-Based Drug Design 184
8.6 Wrapping-Based Selectivity 187
8.7 Targeting Dehydrons is an Effective Strategy for Selectively Blocking Protein Functions 189
8.8 Advantages and Shortcomings in Targeting Activation-Loop Dehydrons 190
Problem 190
References 191

9 Wrapping-Based Re-engineering of an Anticancer Drug to Make it Safer 193
9.1 Building a Safer *Imatinib* 193
9.2 Unique Dynamic Singularities in the Aqueous Interface of the Target Protein Provide the Blueprint for Imatinib Redesign 194
9.3 *In Silico* Assays of the Efficacy of a Wrapping Drug to Displace Labile Interfacial Water 197
9.4 High-Throughput Screening: Test Tube Validation of the Engineered Specificity 197
9.5 In Vitro Assays: Selectively Modulating the Impact of Imatinib 202
9.6 In Vitro Assay of the Selective Anticancer Activity of the Wrapping Design 206
9.7 Enhanced Safety of the Wrapping-Based Imatinib Redesign in Animal Models of Gastrointestinal Stromal Tumor 209
9.8 Controlled Specificity Through Rational Design 212
Problems 212
References 214

10 Biomolecular Interfaces Provide Universal Markers for Drug Specificity and Personalized Medicine 217
10.1 Universal Selectivity Filter for Rationally Designed Kinase Inhibitors: An Imperative for Drug Safety and Personalized Medicine 218

10.2 A Computational Tool Box for Comparative Analysis of Biomolecular Interfaces Across the Human Kinome 219
10.2.1 Dehydron Inference for Proteins with Unreported Structure 219
10.2.2 Alignment of Targetable Regions in the Biomolecular Interface Across the Human Kinome 220
10.3 Is the Biomolecular Interface Pharmacologically Relevant? . . . 221
10.4 Wrapping-Based Target Library for the Human Kinome: Broadening the Technological Base of Drug Discovery 226
10.5 Annotations in a Library of Specificity-Promoting Target Features 228
10.6 Kinome-Wide Dehydron Library as a Biotechnological Resource 233
10.7 Wrapping Specificity for Personalized Molecular Medicine 233
Problem 239
References 240

11 Controlling Induced Folding Through Wrapping Drug Design . . . 243
11.1 Induced Folding: The *Bête Noire* of Drug Design 244
11.2 Wrapping the Floppy Target: A Tractable Case of Induced Folding 244
11.3 Crating Floppy Regions in Drug Targets 247
11.4 Steering Induced Folding: A Dynamic Selectivity Filter 251
11.5 WBZ_4: First JNK Inhibitor Designed Using Dynamic Information 252
11.6 Induced Disruption of Preformed Dehydrons: A Design Strategy Based on Boosting Entropy? 253
Problems 254
References 257

12 Wrapping Drug Combinations for Therapeutic Editing of Side Effects: Systems Biology Meets Wrapping Technology 259
12.1 The Editor Concept in Multicomponent Drug Therapy 259
12.2 Editing Out Pernicious Side Effects Through Combination Drug Therapy 260
12.3 Designing a Therapeutic Editor Using the Wrapping Selectivity Filter 265
12.4 Therapeutic Editing: Toward a Proof of Principle 267
12.5 Future Perspectives for the Editing Therapy 270
Problem 271
References 283

13 Multitarget Control of Drug Impact: A Therapeutic Imperative in Cancer Systems Biology 285
13.1 Is Systems Biology Truly Advocating for Promiscuous Drugs in Anticancer Therapy? 285
13.2 Cleaning Dirty Drugs with the Dehydron Filter: Rationale . . . 288
13.3 Cleaning Dirty Drugs with Dehydron Filters: The Proof of Concept 290
13.4 Taming *Staurosporine* Promiscuity Through the Dehydron Filter 294
13.5 Systems Biology Inspires Wrapping Designs of Multitarget Drugs 297
13.6 Taming Sunitinib Promiscuity to Enhance Safety and Therapeutic Efficacy 303
13.7 Controlled Promiscuity: A Paradigm Shift? 304
Problem 307
References 308

14 Engineering Therapeutic Alignments Between Immune Response and Molecularly Targeted Cancer Treatment 311
14.1 Removal of Drug-Induced Immunosuppressive Effects in Anticancer Drug Therapy: An Imperative for the Pharmaceutical Industry 311
14.2 Therapeutic Shortcomings of Anticancer Drugs that Suppress the Adaptive Immune Response 312
14.2.1 Undesired Cross-Reactivity Modulating the Immune Response 312
14.2.2 Predictably Immunosuppressive Anticancer Drugs 315
14.3 Strategies to Redesign Anticancer Drugs and Turn Them Immunosynergic 315
14.4 Evaluation of Immunosynergic Drug Prototypes 319
14.5 Building Immunosynergies in the Context of HIV-1 Induced Immunosuppression 320
Problem 321
References 321

15 High-Level Quantum Chemistry Empowers the Wrapping Technology for Drug Design 325
15.1 Incorporating Quantum Mechanical Effects into Drug Design 325
15.2 Halogen Bond Synergizing with a Wrapping Interaction: A Novel Motif for Drug Design 326
Problems 328
References 329

Epilogue: New Frontiers 331

Appendix 1: Code for Dehydron Identification 335

Appendix 2: Answers to Problems 343

Index 367

http://www.springer.com/978-3-319-16849-4

Biomolecular Interfaces
Interactions, Functions and Drug Design
Fernandez Stigliano, A.
2015, XIX, 372 p. 145 illus., 59 illus. in color., Hardcover
ISBN: 978-3-319-16849-4